RecruitingNCT05663216

Determinants of Vascular Leakage During Systemic Inflammatory Response Syndrome


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

180 participants

Start Date

May 31, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

BACKGROUND Controlling vascular leakage, which is independently associated with mortality during Sepsis and cardiogenic shock, may be a promising approach during systemic inflammatory response syndrome (SIRS). During a collaborative work between La Pitié-Salpêtrière intensive care unit (ICU) and the unit INSERM U1050 (National Institute oh Health and medical Research), we identified 38 genes associated with capillary leakage during systemic inflammation response syndrome (SIRS) in humans. The aim of this study is to evaluate their possible implication in vascular hyperpermeability associated with METHODS SIRS-PERM is a prospective multicenter cohort study, testing the correlation between the plasma and broncho-alveolar levels of proteins isolated from our first screening, and the level of vascular leakage during SIRS. All patients admitted in the European Georges-Pompidou or La Pitié-Salpêtrière ICU and presenting a SIRS will be eligible for inclusion. Plasma samples will be collected at day 0, D1, D3 and D7, as well as broncho-alveolar lavage samples if clinically indicated. Concentration of each protein will be determined by ELISA in those samples. A statistical association will be then tested between each protein concentration and, for each time-point, the level of capillary leakage (daily weight and fluid balance, extra-vascular lung water index and pulmonary permeability index measured by transpulmonary thermodilution), and ARDS (acute respiratory distress syndrome) severity (PaO2/FiO2 ratio, Murray score and pulmonary compliance). Its link with hemodynamic status, the level of multiple organ failure, and vital status at day 30, will be also assessed. Basing the calculation of the sample size on the variations of VEGF (Vascular endothelial growth factor) expression in our first screening cohort, we calculated a sample size of 180 patients for this study, for a total duration of the study of 5 years. IMPLICATIONS: SIRS-PERM will assess the determinants of capillary leakage during SIRS. It may thus provide a better understanding of the pathophysiology of this disease, with the goal to isolate new markers of severity, as well as new therapeutic targets to treat it. Modulating specifically capillary leakage is indeed a totally new approach during this pathology.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • All patients admitted in the European Georges Pompidou Hospital or La Pitié-Salpêtrière ICU, and exhibiting a systemic inflammatory response syndrome (SIRS), characterized by the following items:
  • Temperature > 38°C ou <36°C
  • Heart rate >90/min
  • Respiratory rate >20/min or PaCO2<32mmHg
  • White cell count > 12 000/mm3 ou < 4 000/mm3

Exclusion Criteria7

  • Age <18 years
  • Decline to participate
  • Pregnancy
  • Cirrhosis Child-Pugh > B
  • Denutrition with BMI<15kg/m2
  • Nephrotic syndrome
  • Persons deprived of their liberty by a judicial or administrative decision (guardianship or tutelage measure)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood sampling

6 ml blood sampling at Day 0, 1, 3, 7. Broncho-alveolar sampling, if performed in routine care.


Locations(2)

Adult Medical-Surgical Intensive Care Unit, Necker Hospital of the Sick Children

Paris, France

Medical Intensive Care Unit, Georges Pompidou European Hospital

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05663216


Related Trials